This case illustrates the risk of fatal vaccine-induced immune thrombotic thrombocytopenia after an AstraZeneca COVID-19 vaccination and emphasizes the need for early recognition and specialized testing, including PF4 ELISA, to improve patient outcomes. This evidence concerns the gene PF4 and COVID-19.